Drug intelligence / Profile preview

SRT003

Development stage: Preclinical
Lead developer: San Rocco Therapeutics
Modality: Gene Therapies

Overview

SRT003 is a gene therapy currently in preclinical development by San Rocco Therapeutics. It is being investigated for the treatment of cardiovascular diseases, with a specific focus on pulmonary arterial hypertension (PAH). As an early-stage candidate within San Rocco's pipeline of therapies for rare and orphan disorders, specific details regarding its molecular target, mechanism of action, and delivery vector have not yet been publicly disclosed.

Beyond the preview

Go deeper on SRT003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SRT003.